Premium
Bcl‐2 overexpression in basaloid proliferations overlying dermatofibromas and basal cell carcinomas
Author(s) -
ROSSEN KRISTIAN,
HAERSLEV TORBEN,
HOUJENSEN KLAUS,
JACOBSEN GRETE KRAG
Publication year - 1997
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/j.1699-0463.1997.tb00537.x
Subject(s) - pathology , basal cell carcinoma , basal (medicine) , biology , carcinogenesis , epidermis (zoology) , immunohistochemistry , cell , lesion , basal cell , cancer , medicine , anatomy , endocrinology , genetics , insulin
Basaloid proliferations overlying dermatofibromas resembling superficial basal cell carcinomas have been interpreted both as reactive/regressive and frankly malignant. Basal cell carcinoma is a slow‐growing tumour, which so far has been regarded as an actively proliferating lesion with a high apoptotic activity. We examined immunohistochemically 6 dermatofibromas with overlying simple hyperplasia, 12 dermatofibromas with overlying basaloid proliferations, and 24 basal cell carcinomas for expression of Ki‐67 protein and bcl‐2 protein. The Ki‐67 labelling index represents an estimate of proliferative activity. Bcl‐2 protein suppresses apoptosis. The Ki‐67 labelling indexes of basaloid proliferations, basal cell carcinomas, and normal epidermis were similar (11–15%, p<0.05, Mann‐Whitney test). Bcl‐2 protein was expressed in all cells of basaloid proliferations, similar to the expression pattern in basal cell carcinomas. We suggest that basaloid proliferations overlying dermatofibromas might have achieved a phenotype that equals an early stage of BCC carcinogenesis.